Page last updated: 2024-08-18

pyrroles and HIV Infections

pyrroles has been researched along with HIV Infections in 55 studies

Research

Studies (55)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (3.64)	18.2507
2000's	18 (32.73)	29.6817
2010's	31 (56.36)	24.3611
2020's	4 (7.27)	2.80

Authors

Authors	Studies
Motati, DR; Uredi, D; Watkins, EB	1
Alves Saldanha, S; Battegay, M; Cavassini, M; Courlet, P; Decosterd, LA; Livio, F; Marzolini, C; Scherrer, A; Stoeckle, M	1
Feist, E; Hoff, P; Ohrndorf, S; Walther, M; Weinerth, J; Wesselmann, H	1
Aldridge, DL; Armitage, LH; Cash, MN; Taylor, JP; Wallet, MA	1
Abebe, M; Abozen, T; Alabanza, PL; Ameni, G; Aseffa, A; Balcha, TT; Baric, RS; Belay, M; Berg, S; Brown, AJ; Chandran, A; Cohen, MS; Coombs, RW; Degli-Angeli, EJ; Demaret, J; Dong, C; Dragavon, JA; Duke, ER; Eltayeb, O; Eron, JJ; Fang, L; Fischer, WA; Forrest, S; Goecker, EA; Harris, KA; Hong, S; Hudgens, MG; Huggett, JF; Jolliffe, DA; Jones, GM; Keys, J; Krajewski, TJ; Li, B; Li, L; Loftis, AJ; Manwandu, H; Martineau, AR; Martineau, HM; Mayito, J; Mollan, KR; Morse, CG; Nikolayevskyy, V; Noursadeghi, M; O'Sullivan, DM; Painter, W; Premkumar, L; Reece, ST; Sheahan, TP; Shuang, S; Szewczyk, LJ; Tayachew, D; Tegegn, M; Tirfie, EA; Tulu, B; Vordermeier, M; Wang, Q; Wang, X; Wohl, DA; Wolfe, CR; Won, JJ; Younis, S; Zewude, A	1
Brehm, JH; Cameron, C; Dupuy, FP; Gavegnano, C; Hurwitz, SJ; Kulpa, DA; Marconi, VC; Ribeiro, SP; Routy, JP; Sabbagh, L; Santos, S; Schinazi, RF; Sékaly, RP; Talla, A	1
Dauwe, K; Hebberecht, L; Mortier, V; Schauvliege, M; Staelens, D; Vancoillie, L; Verhofstede, C	1
Pathania, S; Rawal, RK	1
Giacobbi, NS; Gupta, P; Han, F; Sanyal, A; Sluis-Cremer, N; Vargas, B; Venkatachari, NJ	1
He, XY; Jiang, S; Jiang, XK; Li, L; Liu, S; Lu, L; Qiu, J; Xie, L; Yu, F; Zou, P	1
Barbieri, J; Dewhurst, S; Gantz Marker, MA; Gelbard, HA; Goodfellow, VS; Loweth, CJ; Lu, SM; Marker, DF; Muly, EC; Puccini, JM; Tremblay, MÈ	1
Brown, E; Crane, HM; Delaney, JA; Eron, JJ; Hunt, PW; Kahn, JO; Kitahata, MM; Liu, W; Mathews, WC; Mugavero, MJ; Muñoz, MA; Napravnik, S; Saag, MS; Willig, JH	1
Dewhurst, S; Gelbard, HA; Goodfellow, VS; Loweth, CJ; Marker, DF; Nguyen, T; Polesskaya, O; Pollack, S; Ravula, SB; Sheppard, D; Todd, DE; Wiemann, T; Xu, Y	1
Bosque, A; Detorio, M; Gavegnano, C; Montero, C; Planelles, V; Schinazi, RF	1
Aboulafia, D; Cianfrocca, ME; Deeken, JF; Dezube, BJ; Dowlati, A; Gerecitano, J; Haigentz, M; Henry, DH; Ivy, SP; Little, RF; Mitsuyasu, RT; Moore, PC; Ratner, L; Rudek, MA; Sullivan, R	1
Allenspach, K; Asquith, CR; Hilton, ST; Hofmann-Lehmann, R; Konstantinova, LS; Laitinen, T; Meli, ML; Peräkylä, M; Poso, A; Rakitin, OA	1
Bayigga, L; Elliott, A; Joloba, M; Kaleebu, P; Kambugu, AD; Kamya, MR; Kiragga, A; Mayanja-Kizza, H; Nabatanzi, R; Nakanjako, D; Sekaly, R; Ssinabulya, I	1
Bansal, A; Burkholder, G; Goepfert, PA; Kahan, SM; Overton, ET; Sterrett, S; Westfall, AO; Zajac, AJ	1
Park, SW; Patel, RV	1
Araínga, M; Ciborowski, P; Dash, PK; Gelbard, HA; Gendelman, HE; Goodfellow, VS; Gorantla, S; Guo, D; Haverland, NA; Knibbe-Hollinger, J; Liu, XM; Martinez-Skinner, A; McMillan, JM; Poluektova, LY; Wiederin, JL; Wysocki, BJ; Wysocki, TA; Zhang, G	1
Varvounis, G	1
Ballocca, F; Barbero, U; Biondi-Zoccai, G; Bonora, S; Calcagno, A; Cannillo, M; Cerrato, E; D'Ascenzo, F; DiNicolantonio, JJ; Gaita, F; Gasparini, M; Gili, S; Grosso Marra, W; Lavie, CJ; Lonni, E; Mancone, M; Montefusco, A; Moretti, C; Omedè, P; Pianelli, M	1
Cunyat, F; McCune, JM; Rainho, JN; Stevenson, M; Swainson, L; West, B	1
Cadeddu, M; Corona, A; Cosconati, S; Costi, R; Delelis, O; di Leva, FS; di Santo, R; Esposito, F; Madia, VN; Novellino, E; Pescatori, L; Rigogliuso, G; Subra, F; Tramontano, E	1
Adame, A; Fields, JA; Florio, J; He, JJ; Masliah, E; Metcalf, J; Overk, C; Rockenstein, E; Spencer, B; Wrasidlo, W	1
Han, Y; Mesplède, T; Quan, Y; Wainberg, MA; Xu, H	1
Altieri, A; Belov, DS; Curreli, F; Debnath, AK; Kurkin, AV; Kwon, YD; Kwong, PD; Ramesh, RR	1
Critchfield, J; Deeks, SG; Lee, E; Lollo, N; Price, RW; Probasco, JC; Spudich, SS	1
Calza, L; Chiodo, F; Colangeli, V; Manfredi, R; Pavoni, M; Pocaterra, D	1
Arab Chamjangali, M	1
Schmidt, C	1
Crane, HM; Crane, PK; Harrington, RD; Kitahata, MM; Knopp, RH; Kosel, BW; Mugavero, MJ; Saag, MS; Singh, S; Willig, JH	1
Bavaro, M; Brandt, C; Crum-Cianflone, N; Decker, CF; Follmann, D; Ganesan, A; Higgins, J; Maldarelli, F; Metcalf, J; Qin, J; Rehm, C; Sklar, P; Tasker, S; Vita, J	1
Clumeck, N; De Wit, S; Delforge, M; Necsoi, CV	1
Cong, XJ; Hu, LM; Kong, R; Kui, ZY; Liu, B; Tan, JJ; Wang, CX; Yang, LF; Zhang, B	1
An, H; Chang, J; Cui, Y; Dong, L; Ge, Z; Guo, X; Hu, W; Li, Y; Pan, Z; Song, C; Tao, L; Wang, Q; Wang, S; Yang, Q; Yu, X	1
Abdelmajeid, A; Abo-Dya, NE; Avan, I; Debnath, AK; Ibrahim, TS; Jiang, S; Katritzky, AR; Lu, H; Tala, SR; Zou, P	1
Grubb, JR; Onen, NF; Overton, ET; Presti, R	1
González, M; González-Santos, P; Márquez, M; Palacios, R; Ruiz, J; Santos, J; Valdivielso, P	1
Coull, JJ; Dervan, PB; He, G; Margolis, DM; Melander, C; Rucker, VC	1
Gill, MJ; Mah Ming, JB	1
Bosch, RJ; Brodie, SJ; Corey, L; Coull, JJ; Dervan, PB; Margolis, DM; Melander, C; Rucker, VC; Sodora, DL; Ylisastigui, L	1
Aberg, JA; Alston, BL; Brobst, SW; Fichtenbaum, CJ; Gerber, JG; Rosenkranz, SL; Segal, Y; Vega, JM; Yang, A	1
Blanco, J; Clotet, B; Moltó, J; Negredo, E; Pérez-Alvarez, N; Puig, J; Rey-Joly, C; Romeu, J; Ruiz, L	1
Deig, E; Guelar, A; Guil, J; Pedrol, E; Rodríguez-Martín, M; Soler, A	1
Palacios Muñoz, R; Santos González, J	1
Bennett, MT; Bondy, GP; Johns, KW	1
Gaughan, JP; Klibanov, OM; Tedaldi, EM; van den Berg-Wolf, M	1
Flexner, C; Ginsberg, R; Hamzeh, FM; Haubrich, RH; Hirsch, M; Lederman, MM; Lietman, P; Pettinelli, CP; Richman, DD; Spector, SA	1
Martín, T; Murillas, J; Portero, JL; Ramos, A	1
Currier, JS	1
Almerico, AM; Barraja, P; Delpiano, D; Diana, P; Lauria, A; Loddo, R; Mingoia, F; Montalbano, A; Musiu, C; Sanna, L; Setzu, MG	1
Castro, JG; Gutierrez, L	1

Reviews

5 review(s) available for pyrroles and HIV Infections

Article	Year
The Discovery and Development of Oxalamide and Pyrrole Small Molecule Inhibitors of gp120 and HIV Entry - A Review. Current topics in medicinal chemistry, 2019, Volume: 19, Issue:18 Topics: Amides; Anti-HIV Agents; Drug Discovery; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Pyrroles; Small Molecule Libraries	2019
Pyrrolopyrimidines: An update on recent advancements in their medicinal attributes. European journal of medicinal chemistry, 2018, Sep-05, Volume: 157 Topics: Animals; Anti-Retroviral Agents; Antineoplastic Agents; HIV Infections; Humans; Male; Molecular Structure; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Pyrroles; Structure-Activity Relationship	2018
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase. Bioorganic & medicinal chemistry, 2015, Sep-01, Volume: 23, Issue:17 Topics: Anti-HIV Agents; Drug Discovery; HIV; HIV Fusion Inhibitors; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; Humans; Pyrroles; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Virus Replication	2015
An Update on the Synthesis of Pyrrolo[1,4]benzodiazepines. Molecules (Basel, Switzerland), 2016, Jan-28, Volume: 21, Issue:2 Topics: Anti-HIV Agents; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Cyclization; DNA; HIV Infections; Humans; Molecular Structure; Neoplasms; Pyrroles; Structure-Activity Relationship	2016
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. European heart journal, 2016, Dec-21, Volume: 37, Issue:48 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Primary Prevention; Pyrroles; Rosuvastatin Calcium; Simvastatin	2016

Trials

9 trial(s) available for pyrroles and HIV Infections

Article	Year
A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer, 2014, Apr-15, Volume: 120, Issue:8 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; HIV Infections; Humans; Indoles; Male; Middle Aged; Neoplasms; Pyrroles; Ritonavir; Sunitinib	2014
Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial. Tropical medicine & international health : TM & IH, 2015, Volume: 20, Issue:3 Topics: Adult; Anti-HIV Agents; Atorvastatin; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocyte Activation; Lymphocyte Depletion; Male; Middle Aged; Pyrroles; Uganda; Viral Load	2015
Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study. Neurology, 2008, Aug-12, Volume: 71, Issue:7 Topics: Adult; Anti-HIV Agents; Atorvastatin; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Heptanoic Acids; HIV Infections; HIV-1; Humans; Male; Neopterin; Pilot Projects; Pyrroles; Viral Load	2008
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Current HIV research, 2008, Volume: 6, Issue:6 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Viral Load	2008
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. The Journal of infectious diseases, 2011, Mar-15, Volume: 203, Issue:6 Topics: Adult; Atorvastatin; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Over Studies; Double-Blind Method; Heptanoic Acids; HIV Infections; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Placebos; Pyrroles; RNA, Viral	2011
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. Journal of acquired immune deficiency syndromes (1999), 2005, Jul-01, Volume: 39, Issue:3 Topics: Adult; Alkynes; Anti-HIV Agents; Atorvastatin; Benzoxazines; Cholesterol, LDL; Cyclopropanes; Drug Interactions; Female; Heptanoic Acids; HIV Infections; HIV Seronegativity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Oxazines; Pravastatin; Pyrroles; Simvastatin	2005
The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy. AIDS (London, England), 2006, Feb-28, Volume: 20, Issue:4 Topics: Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Heptanoic Acids; HIV Infections; HIV-1; Humans; Pilot Projects; Pyrroles; RNA, Viral; Virus Replication	2006
[Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia]. Medicina clinica, 2006, Jul-15, Volume: 127, Issue:7 Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atorvastatin; Female; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles	2006
A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. The Journal of infectious diseases, 1995, Volume: 172, Issue:5 Topics: Adult; Antiviral Agents; Benzodiazepines; CD4 Lymphocyte Count; Didanosine; Dose-Response Relationship, Drug; Female; Gene Products, tat; HIV Core Protein p24; HIV Infections; Humans; Male; Middle Aged; Pyrroles; tat Gene Products, Human Immunodeficiency Virus; Time Factors; Zidovudine	1995

Other Studies

41 other study(ies) available for pyrroles and HIV Infections

Article	Year
Real-life management of drug-drug interactions between antiretrovirals and statins. The Journal of antimicrobial chemotherapy, 2020, 07-01, Volume: 75, Issue:7 Topics: Cohort Studies; Drug Interactions; Fluorobenzenes; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pharmaceutical Preparations; Pyrroles	2020
[Successful treatment of adult Still's disease with tofacitinib in a HIV-2 positive female patient]. Zeitschrift fur Rheumatologie, 2020, Volume: 79, Issue:10 Topics: Adult; Female; HIV Infections; HIV-2; Humans; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Still's Disease, Adult-Onset; Treatment Outcome	2020
Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA. Biology open, 2020, 12-21, Volume: 9, Issue:12 Topics: CD4-Positive T-Lymphocytes; Diterpenes; Gene Expression Regulation; Harmine; HIV Infections; HIV-1; Humans; Lymphocyte Activation; Nylons; Protein Kinase C; Pyrroles; RNA-Binding Proteins; Transcription Factors; Virus Activation; Virus Latency	2020
The Lancet. Microbe, 2021, Volume: 2, Issue:6 Topics: Cross-Sectional Studies; DNA; Ethiopia; HeLa Cells; HIV Infections; Humans; Hydrogen Peroxide; Isoniazid; Latent Tuberculosis; Leukocytes, Mononuclear; Manganese Compounds; Methylene Blue; Microscopy, Confocal; Mycobacterium tuberculosis; Nanocomposites; Nanoparticles; Neoplasms; Oxides; Photochemotherapy; Photosensitizing Agents; Photothermal Therapy; Polyethylene Glycols; Polymers; Prospective Studies; Pyrroles; Tuberculin Test; Tuberculosis; Tumor Microenvironment	2021
Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors. PLoS pathogens, 2017, Volume: 13, Issue:12 Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; HIV Infections; HIV-1; Humans; Janus Kinase Inhibitors; Nitriles; Piperidines; Pyrazoles; Pyrimidines; Pyrroles; Virus Latency; Virus Replication	2017
Frequency of occurrence of HIV-1 dual infection in a Belgian MSM population. PloS one, 2018, Volume: 13, Issue:4 Topics: Adult; Belgium; High-Throughput Nucleotide Sequencing; HIV Envelope Protein gp120; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Middle Aged; Peptide Fragments; Phylogeny; Prevalence; Pyrroles; Retrospective Studies; Superinfection	2018
Inhibitors of Signaling Pathways That Block Reversal of HIV-1 Latency. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:2 Topics: Anti-HIV Agents; Benzamides; CD4-Positive T-Lymphocytes; Cell Line; HIV Infections; HIV-1; Humans; Pyrazoles; Pyrroles; Signal Transduction; Virus Activation	2019
Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41. Bioorganic & medicinal chemistry, 2013, Dec-01, Volume: 21, Issue:23 Topics: Anti-HIV Agents; Cell Line; Drug Design; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Molecular Docking Simulation; Pyrroles; Small Molecule Libraries	2013
The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2013, Jun-12, Volume: 33, Issue:24 Topics: Animals; Bone Marrow Transplantation; Cell Line, Transformed; Cells, Cultured; CX3C Chemokine Receptor 1; Cytokines; Disease Models, Animal; Embryo, Mammalian; Gene Products, tat; Green Fluorescent Proteins; Hippocampus; HIV Infections; HIV-1; Humans; Inflammation; MAP Kinase Kinase Kinases; Mice; Mice, Transgenic; Microscopy, Immunoelectron; Mitogen-Activated Protein Kinase Kinase Kinase 11; Neuroprotective Agents; Phagocytosis; Phosphorylation; Pyridines; Pyrroles; Rats; Receptors, Chemokine; Signal Transduction; Statistics, Nonparametric; tat Gene Products, Human Immunodeficiency Virus; Time Factors; Transfection	2013
Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care. Journal of acquired immune deficiency syndromes (1999), 2013, Nov-01, Volume: 64, Issue:3 Topics: Adult; Alabama; Atorvastatin; California; CD4-Positive T-Lymphocytes; Cohort Studies; Comparative Effectiveness Research; Drug Interactions; Female; Fenofibrate; Fish Oils; Gemfibrozil; Heptanoic Acids; HIV Infections; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; North Carolina; Practice Guidelines as Topic; Pyrroles; Retrospective Studies; San Francisco; Treatment Outcome; Triglycerides; Washington	2013
Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. Journal of medicinal chemistry, 2013, Oct-24, Volume: 56, Issue:20 Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Blood-Brain Barrier; Brain; Carbazoles; Cells, Cultured; Cognition Disorders; Drug Discovery; HIV Infections; Humans; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase Kinase Kinase 11; Models, Chemical; Molecular Structure; Monocytes; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Pyrroles; tat Gene Products, Human Immunodeficiency Virus; Tumor Necrosis Factor-alpha	2013
Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:4 Topics: Animals; Cells, Cultured; HIV Infections; HIV-1; Humans; Janus Kinase 1; Janus Kinase 2; Lymphocytes; Macaca mulatta; Macrophages; Nitriles; Piperidines; Pyrazoles; Pyrimidines; Pyrroles; Virus Replication	2014
Evaluation of the antiviral efficacy of bis[1,2]dithiolo[1,4]thiazines and bis[1,2]dithiolopyrrole derivatives against the nucelocapsid protein of the Feline Immunodeficiency Virus (FIV) as a model for HIV infection. Bioorganic & medicinal chemistry letters, 2014, Jun-15, Volume: 24, Issue:12 Topics: Animals; Capsid Proteins; Cats; Cell Line; Cell Survival; Disease Models, Animal; HIV Infections; Humans; Immunodeficiency Virus, Feline; Molecular Structure; Pyrroles; Small Molecule Libraries; Thiazines	2014
Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients. AIDS (London, England), 2014, Nov-13, Volume: 28, Issue:17 Topics: Anti-Retroviral Agents; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; HIV Infections; HIV-1; Humans; Immunologic Factors; Interferon-gamma; Lymphocyte Activation; Pravastatin; Pyrroles; Retrospective Studies; T-Lymphocyte Subsets; T-Lymphocytes	2014
The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy. Nanomedicine : nanotechnology, biology, and medicine, 2016, Volume: 12, Issue:1 Topics: Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; MAP Kinase Kinase Kinases; Mice; Mice, SCID; Mitogen-Activated Protein Kinase Kinase Kinase 11; Nanocapsules; Protein Kinase Inhibitors; Pyridines; Pyrroles; Treatment Outcome	2016
Colony-Stimulating Factor 1 Receptor Antagonists Sensitize Human Immunodeficiency Virus Type 1-Infected Macrophages to TRAIL-Mediated Killing. Journal of virology, 2016, 07-15, Volume: 90, Issue:14 Topics: Aminopyridines; CD4-Positive T-Lymphocytes; Cells, Cultured; HIV Infections; HIV-1; Humans; Macrophage Colony-Stimulating Factor; Macrophages; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; TNF-Related Apoptosis-Inducing Ligand; Virus Latency; Virus Replication	2016
New insights into the interaction between pyrrolyl diketoacids and HIV-1 integrase active site and comparison with RNase H. Antiviral research, 2016, Volume: 134 Topics: Anti-HIV Agents; Binding Sites; Catalytic Domain; Drug Resistance, Viral; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Models, Molecular; Molecular Structure; Mutagenesis, Site-Directed; Pyrroles; Ribonuclease H; Structure-Activity Relationship; Virus Replication	2016
The anticancer drug sunitinib promotes autophagyand protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration. Journal of neurovirology, 2017, Volume: 23, Issue:2 Topics: Acyltransferases; Animals; Antineoplastic Agents; Autophagy; Cognitive Dysfunction; Cyclin-Dependent Kinase 5; Disease Models, Animal; Disease Progression; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Indoles; Mice; Mice, Transgenic; Microtubule-Associated Proteins; Neurons; Pyrroles; Sequestosome-1 Protein; Signal Transduction; Sunitinib; tat Gene Products, Human Immunodeficiency Virus; Transgenes	2017
JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1. Journal of virology, 2017, 05-01, Volume: 91, Issue:9 Topics: Binding Sites; CD4 Antigens; CD4-Positive T-Lymphocytes; env Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV-1; Humans; Interleukin-2; Janus Kinases; Nitriles; Piperidines; Pyrazoles; Pyrimidines; Pyrroles; Pyrrolidines; Signal Transduction; STAT Transcription Factors; Sulfonamides; Tetradecanoylphorbol Acetate; TOR Serine-Threonine Kinases; Virus Internalization; Virus Replication	2017
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120. Journal of medicinal chemistry, 2017, 04-13, Volume: 60, Issue:7 Topics: Anti-HIV Agents; Biomimetic Materials; CD4 Antigens; Cell Line; Crystallography, X-Ray; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Molecular Docking Simulation; Molecular Targeted Therapy; Pyrroles; Structure-Activity Relationship; Thiazoles; Virus Internalization	2017
Modelling of cytotoxicity data (CC50) of anti-HIV 1-[5-chlorophenyl) sulfonyl]-1H-pyrrole derivatives using calculated molecular descriptors and Levenberg-Marquardt artificial neural network. Chemical biology & drug design, 2009, Volume: 73, Issue:4 Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Models, Biological; Models, Molecular; Molecular Structure; Neural Networks, Computer; Pyrroles; Quantitative Structure-Activity Relationship; Software; Sulfonamides	2009
The cancer-HIV/AIDS treatment conundrum. Journal of the National Cancer Institute, 2010, Nov-03, Volume: 102, Issue:21 Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Cytochrome P-450 CYP3A; Drug Administration Schedule; Drug Antagonism; HIV Infections; HIV Protease Inhibitors; Humans; Indoles; Neoplasms; Pyrroles; Risk Factors; Ritonavir; Sunitinib	2010
Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011, Feb-01, Volume: 52, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Cohort Studies; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Serum; Sulfonamides	2011
Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load. AIDS (London, England), 2011, Jun-19, Volume: 25, Issue:10 Topics: ADP-ribosyl Cyclase 1; Atorvastatin; CD4-Positive T-Lymphocytes; Down-Regulation; Female; Heptanoic Acids; HIV Infections; Humans; Lymphocyte Activation; Male; Membrane Glycoproteins; Pyrroles; Viral Load	2011
Computer-aided design, synthesis, and biological activity evaluation of potent fusion inhibitors targeting HIV-1 gp41. Medicinal chemistry (Shariqah (United Arab Emirates)), 2011, Volume: 7, Issue:4 Topics: Anti-HIV Agents; Benzoates; Computer-Aided Design; Drug Design; Drug Evaluation, Preclinical; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Hydroxybenzoates; Inhibitory Concentration 50; Molecular Structure; Molecular Targeted Therapy; Pyrroles	2011
Synthesis and anti-HIV-1 activity of 4-substituted-7-(2'-deoxy-2'-fluoro-4'-azido-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine analogues. Bioorganic & medicinal chemistry letters, 2011, Nov-15, Volume: 21, Issue:22 Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Pyrimidines; Pyrroles; Ribonucleosides	2011
Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41. Bioorganic & medicinal chemistry letters, 2011, Nov-15, Volume: 21, Issue:22 Topics: Drug Design; Furans; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Pyrroles	2011
Reply to Ganesan et al. The Journal of infectious diseases, 2012, Feb-01, Volume: 205, Issue:3 Topics: Acquired Immunodeficiency Syndrome; Antigens, CD; Heptanoic Acids; HIV Infections; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocyte Activation; Male; Pyrroles; Receptors, CCR5; Receptors, CXCR4; RNA, Viral; T-Lymphocytes	2012
Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy. Journal of acquired immune deficiency syndromes (1999), 2002, Aug-15, Volume: 30, Issue:5 Topics: Adult; Aged; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Female; Heptanoic Acids; HIV Infections; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles	2002
Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides. Journal of virology, 2002, Volume: 76, Issue:23 Topics: Base Sequence; Cell Line; DNA-Binding Proteins; DNA, Viral; Erythroid-Specific DNA-Binding Factors; Gene Expression; Genes, Viral; HeLa Cells; Histone Deacetylases; HIV Infections; HIV Long Terminal Repeat; HIV-1; Humans; Imidazoles; In Vitro Techniques; Molecular Sequence Data; Nylons; Pyrroles; RNA-Binding Proteins; Transcription Factors	2002
Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS patient care and STDs, 2003, Volume: 17, Issue:5 Topics: Adult; Anti-Bacterial Agents; Atorvastatin; Clarithromycin; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lopinavir; Male; Pyrimidinones; Pyrroles; Rhabdomyolysis; Ritonavir	2003
Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. The Journal of infectious diseases, 2004, Oct-15, Volume: 190, Issue:8 Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Enzyme Inhibitors; Histone Deacetylases; HIV Core Protein p24; HIV Infections; HIV Long Terminal Repeat; HIV-1; Humans; Imidazoles; Nylons; Pyrroles; RNA, Viral; Virus Latency	2004
[HIV infection: from Pneumocystis to statins]. Medicina clinica, 2006, Jul-15, Volume: 127, Issue:7 Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pneumocystis Infections; Pyrroles; Risk Factors	2006
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids in health and disease, 2007, Jun-13, Volume: 6 Topics: Adult; Aged; Anti-Retroviral Agents; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Protease Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides	2007
Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients. AIDS patient care and STDs, 2008, Volume: 22, Issue:6 Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Azetidines; Cholesterol, LDL; Drug Administration Schedule; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Lopinavir; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Ritonavir; Treatment Outcome	2008
Atorvastatin for protease inhibitor-related hyperlipidaemia. AIDS (London, England), 1999, Jul-30, Volume: 13, Issue:11 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Male; Pyrroles; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir	1999
How to manage metabolic complications of HIV therapy: what to do while we wait for answers. The AIDS reader, 2000, Volume: 10, Issue:3 Topics: Anabolic Agents; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; Exercise Therapy; Gemfibrozil; Growth Hormone; Guidelines as Topic; Heptanoic Acids; HIV Infections; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipodystrophy; Metabolic Diseases; Metformin; Nucleosides; Protease Inhibitors; Pyrroles; Reverse Transcriptase Inhibitors; Risk Factors; Thiazoles; Thiazolidinediones	2000
ICAAC: nelfinavir interacts with statins and an antiseizure drug. The AIDS reader, 2000, Volume: 10, Issue:11 Topics: Anticholesteremic Agents; Anticonvulsants; Atorvastatin; Drug Interactions; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nelfinavir; Phenytoin; Pyrroles; Simvastatin	2000
. . . from the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Research initiative, treatment action : RITA, 2000, Volume: 6, Issue:4 Topics: Anti-HIV Agents; Anti-Infective Agents; Antineoplastic Agents; Atorvastatin; Drug Administration Schedule; Drug Interactions; Drug Resistance, Microbial; Heptanoic Acids; HIV Infections; Humans; Pyrroles; Rhabdomyolysis	2000
Pyrrolo[1,2-f]phenanthridines and related non-rigid analogues as antiviral agents. European journal of medicinal chemistry, 2002, Volume: 37, Issue:1 Topics: Anti-HIV Agents; Cell Line; Cell Survival; HIV Infections; HIV-1; Humans; Models, Molecular; Phenanthridines; Pyrroles; Structure-Activity Relationship	2002
Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. The American journal of medicine, 2002, Apr-15, Volume: 112, Issue:6 Topics: Acute Kidney Injury; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Delavirdine; Drug Interactions; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Mixed Function Oxygenases; Pyrroles; Rhabdomyolysis	2002